- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT IN RELATION TO CLINICAL TRIAL APPLICATION FOR 9MW5211 INJECTION APPROVED BY NMPA | - | HKEx | ||
| 23.06. | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT REGARDING THE RECEIPT OF NMPA APPROVAL FOR THE CLINICAL TRIAL APPLICATION OF 6MW5311 FOR INJECTION | - | HKEx | ||
| MABWELL SHANGHAI BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 18.06. | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT REGARDING THE ORAL AND POSTER PRESENTATIONS OF THE LATEST CLINICAL DATA OF 9MW2821 AT THE 2026 ESMO CONGRESS ... | 1 | HKEx | ||
| 18.06. | MABWELL-B (02493): APPOINTMENT OF MEMBERS OF SENIOR MANAGEMENT | 1 | HKEx | ||
| 18.06. | MABWELL-B (02493): CHANGE OF AUTHORISED REPRESENTATIVE | - | HKEx | ||
| 18.06. | MABWELL-B (02493): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 18.06. | MABWELL-B (02493): ELECTION OF EMPLOYEE REPRESENTATIVE DIRECTOR | - | HKEx | ||
| 18.06. | MABWELL-B (02493): RETIREMENT OF DIRECTORS ELECTION OF THE THIRD SESSION OF THE BOARD OF DIRECTORS ELECTION OF CHAIRMAN OF THE THIRD SESSION OF THE BOARD ... | 1 | HKEx | ||
| 18.06. | MABWELL-B (02493): POLL RESULTS OF THE 2026 THIRD EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 12.06. | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT REGARDING THE RECEIPT OF FDA CLEARANCE FOR THE CLINICAL TRIAL APPLICATION OF 6MW5311 FOR INJECTION | - | HKEx | ||
| 05.06. | MABWELL-B 9MW5211 Injection Clinical Trial Application Approved by NMPA | 2 | AASTOCKS | ||
| 04.06. | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT IN RELATION TO CLINICAL TRIAL APPLICATION FOR 9MW5211 INJECTION APPROVED BY NMPA | 3 | HKEx | ||
| 01.06. | MABWELL-B (02493): POLL RESULTS OF THE 2026 SECOND EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 29.05. | MABWELL-B (02493): REMUNERATION MANAGEMENT SYSTEM FOR DIRECTORS AND SENIOR MANAGEMENT | - | HKEx | ||
| 29.05. | MABWELL-B (02493): ARTICLES OF ASSOCIATION | - | HKEx | ||
| 29.05. | MABWELL-B (02493): AMENDMENTS TO THE ARTICLES OF ASSOCIATION | - | HKEx | ||
| 21.05. | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT REGARDING THE ORAL AND POSTER PRESENTATIONS OF LATEST CLINICAL DATA ON 9MW2821 AT THE 2026 AMERICAN SOCIETY ... | 2 | HKEx | ||
| 20.05. | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT REGARDING THE APPROVAL OF SUPPLEMENTARY APPLICATION FOR ADDITIONAL INDICATIONS OF MAIWEIJIAN INJECTION | 1 | HKEx | ||
| 09.05. | World's First | Mabwell's 9MW5211 Receives FDA Clearance for Clinical Trial Application | 410 | PR Newswire | SHANGHAI, May 8, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced... ► Artikel lesen | |
| 08.05. | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT REGARDING THE RECEIPT OF U.S. FDA CLEARANCE FOR THE CLINICAL TRIAL APPLICATION OF 9MW5211 INJECTION | 1 | HKEx |
1 2 3 Weiter >>
52 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 132,66 | +0,04 % | Deal Dispatch: Penske Buys Vox Media's Digital Brands, AbbVie Acquires Apogee Therapeutics For $10.9 Billion, Camp Mystic Bankruptcy | ||
| PRAXIS PRECISION MEDICINES | 349,93 | -0,18 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| TANGO THERAPEUTICS | 32,550 | -0,03 % | Jefferies upgrades Tango Therapeutics stock rating on cancer trial data | ||
| VERA THERAPEUTICS | 43,130 | -0,05 % | Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy | Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN)Revised ORIGIN 3 eGFR... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 109,43 | +0,10 % | Top Biotech Gainers: TECH Bought Out, MSLE On Watch, KYMR Hits New High, What's The Buzz At SLS? | OTTAWA (dpa-AFX) - Today's top gainers in the biotech space include Bio-Techne, following acquisition news; Satellos Bioscience, gearing up to present new DMD data next month; and Kymera, which... ► Artikel lesen | |
| ERASCA | 18,290 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,740 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 35,340 | 0,00 % | Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation? | ||
| MINERALYS THERAPEUTICS | 26,880 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 62,41 | 0,00 % | Kiniksa Pharmaceuticals Aktie markiert Rekordhoch bei 59,89 USD | ||
| ABSCI | 11,345 | -0,04 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,310 | -0,07 % | Bernstein hebt Kursziel für Summit Therapeutics Aktie aufgrund von Studienaussichten an | ||
| RELAY THERAPEUTICS | 19,740 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| BEAM THERAPEUTICS | 34,950 | 0,00 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 50,86 | +0,02 % | Jones Trading raises Enliven Therapeutics price target on CML trials |
Das Unternehmen MABWELL SHANGHAI BIOSCIENCE CO LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MABWELL SHANGHAI BIOSCIENCE CO LTD finden Sie auf Wallstreet Online.